If you have been reading about PPAR delta and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-24. Numbers and descriptions here follow the published literature rather than marketing material.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Dinoflagellates are the primary source of dinosteral. Dinoflagellates are unicellular, aquatic organisms that live in both marine and inland environments and are a prominent constituent of phytoplankton. Dinoflagellates are often characterized by their uncommon sterol distribution, dominated by 4α-methyl sterols derived from lanosterol rather than cycloartenol. In many cases, the most abundant sterol in dinoflagellates is dinosterol. Dinosterol is often used a biomarker in geochemical research because it is produced almost exclusively by dinoflagellates and is found in many environments. In addition to several species of dinoflagellates, dinosterol has also been isolated from the diatom Nivicula sp. (CS-46c) collected from Port Hacking, New South Wales, Australia.
==== Dame Commander of the Order of the British Empire (DBE) ==== Civil Dr Margaret Ebunoluwa Aderin, , Chancellor, University of Leicester. For services to Science Education and to Diversity. Amanda Jayne Blanc, Group Chief Executive Officer, Aviva. For services to Business, to Gender Equality and to Net-Zero. Professor Sonia Boyce, , Artist. For services to Art. Jilly Cooper, , Author. For services to Literature and to Charity. Felicity Ann Dahl, Founder, Roald Dahl's Marvellous Children's Charity and the Roald Dahl Museum and Story Centre. For services to Philanthropy, to Literature and to Young People. Dr Jennifer Dixon, , Chief Executive, The Health Foundation. For services to the NHS and to Public Health. Tristina Adele Harrison, Chief Executive Officer, TalkTalk Group. For services to Telecommunications. Dianne Michèle Jeffrey, , lately Trustee and Founder Chair, Age International. For services to Older People Abroad and to the community in Derbyshire. Professor Valerie Joan Lund, , Emeritus Professor in Rhinology, University College London. For services to Rhinology. Siobhain Ann McDonagh, , Member of Parliament for Mitcham and Morden. For Parliamentary and Political Service. Ruth Elizabeth Miskin, , Children's Reading Expert, Read Write Inc. For services to Education. Marit Mohn, Philanthropist. For services to Philanthropy. Professor Molly Morag Stevens, , John Black Professor of Bionanoscience, University of Oxford and Professor, Imperial College London. For services to Medicine.
== Detrital zircon data == Depending on the detrital zircon study, there should be different variables included for analysis. There are two main types of data, analyzed zircon data (quantifiable data and imagery/descriptive data), and sample (where they extract the zircon grains) data. Details are listed in Table 2.
Sources: en.wikipedia.org
A review of the UKPDS, Action to Control Cardiovascular Risk in Diabetes (ACCORD), Advance and Veterans Affairs Diabetes Trials (VADT) estimated that the risks of the main complications of diabetes (diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, and macrovascular disease) decreased by about 3% for every 1 mmol/mol decrease in HbA1c. However, a trial by ACCORD designed specifically to determine whether reducing HbA1c below 42 mmol/mol (6.0 DCCT %) using increased amounts of medication would reduce the rate of cardiovascular events found higher mortality with this intensive therapy, so much so that the trial was terminated 17 months early. Practitioners must consider patients' health, their risk of hypoglycemia, and their specific health risks when setting a target HbA1c level. Because patients are responsible for averting or responding to their own hypoglycemic episodes, their input and the doctors' assessments of the patients' self-care skills are also important. Persistent elevations in blood sugar (and, therefore, HbA1c) increase the risk of long-term vascular complications of diabetes, such as coronary disease, heart attack, stroke, heart failure, kidney failure, blindness, erectile dysfunction, neuropathy (loss of sensation, especially in the feet), gangrene, and gastroparesis (slowed emptying of the stomach). Poor blood glucose control also increases the risk of short-term complications of surgery, such as poor wound healing.
==== Travelling wave ion mobility spectrometry (TWIMS) ==== In TWIMS, ions are separated according to their mobility through a travelling wave in a gas filled cell. Both radio-frequency (RF) and direct current (DC) voltages are applied to a series of ring electrodes called a stacked ring ion guide (SRIG) to confine the ions and create a travelling wave. Based on the speed and magnitude of the travelling wave, ions can be separated. Smaller ions have higher mobility through the wave due to fewer collisions with gas molecules and exit the cell faster than ions of lower mobility (larger ions). Similar to DTIMS, CCS values of ions can be calculated with TWIMS using a calibration derived with known standards. A commercial example of the TWIMS-MS instrumentation is Waters Corp Synapt G2-S instrument.
== Services == Flagler Global Logistics offers consolidation and deconsolidation, multimodal transportation, warehouse management, Foreign Trade Zone, and dry and refrigerated cargo services, as well as commercial real estate development. FGL is the only company with direct connectivity to PortMiami, Port Everglades, and Miami International Airport. FGL currently operates or is developing, six Class-A logistics and distribution facilities throughout Florida. In total, FGL's assets include more than 1 million square feet of move-in ready, Class-A warehouse and distribution space, as well as more than 2,000 gross acres of land holdings throughout Florida that could accommodate nearly 24 million square feet of industrial development. Flagler Global Logistics flagship multimodal distribution complex—South Florida Logistics Center—is located adjacent to the Miami International Airport, with exclusive rail connectivity via the Florida East Coast Railway to South Florida's busiest ports—PortMiami and Port Everglades. The more-than-200-acre South Florida Logistics Center opened in November 2013. Its centerpiece is Flagler Global Logistics’ cold-chain management facility. When fully built out, the center will consist up to 2 million square feet of industrial space. South Florida Logistics Center is an approved magnet site for Foreign Trade Zone No. 281. Tenants include Goodyear and the Flying Food Group.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.